Neurocrine Biosciences’ Post

We are proud to sponsor and attend The MAGIC Foundation’s 30th Annual Convention, which aims to provide an educational experience for parents of children, as well as affected adults, living with an endocrine disorder. The MAGIC Foundation provides support services for the families of children afflicted with a wide variety of chronic and/or critical disorders, syndromes and diseases that affect a child’s growth.

July is Bebe Moore Campbell National Minority Health Awareness Month, a time to highlight the unique challenges faced by Black, Indigenous, and people of color (BIPOC) in their mental health journey. For more information, visit the BIPOC Mental Health Resource Center at https://lnkd.in/gaYP2mwX #BIPOCMentalHealth Mental Health America  

We are pleased to announce the U.S. FDA has accepted our two New Drug Applications (NDAs) with a Priority Review designation for an investigational treatment of classic congenital adrenal hyperplasia (CAH) in children, adolescents and adults. Read more: https://lnkd.in/g2pVurx3

Congenital Adrenal Hyperplasia (CAH) is a rare, lifelong genetic condition involving the adrenal glands that affects up to approximately 30,000 people in the United States. To learn more about #CAH, including symptoms and treatment challenges, visit WHAT THE CAH?!: https://lnkd.in/giQxuvrx #CAHAwarenessMonth

As we welcome our 2024 Summer Interns, Chengyu Bi, Associate Scientist, In Vitro Pharmacology, reflects on her own experience with the internship program and takeaways after joining Neurocrine’s Research and Development Team full-time. The 10-week internship program gives students and recent graduates an opportunity to gain work experience within the life sciences field across various departments, including Corporate Affairs, Research & Development, Business Development, and more!

Juneteenth recognizes the end of slavery in the United States and honors the resilience and achievements of Black Americans. Learn more about the legacy of Juneteenth: https://lnkd.in/gqvPZFF

Happy #Pride. Neurocrine is committed to an inclusive culture that values and supports the LGBTQ+ community. May this month be a time of pride, joy, and unity and an opportunity to show up for LGBTQ+ people in our daily lives. #PrideMonth2024

Congenital Adrenal Hyperplasia (CAH) is a rare, genetic condition that results in an enzyme deficiency that alters the production of adrenal hormones. June is CAH Awareness Month, which aims to recognize individuals and their families impacted by this condition. Learn more about CAH in this article, including the personal story of a person living with CAH. https://lnkd.in/dmCU_zjb #CAHAwarenessMonth

Today we announced that the complete study results from the CAHtalyst™ Phase 3 Adult and Pediatric studies have been published in The New England Journal of Medicine (NEJM Group). In addition to being published in the journal, the data were also shared at Endocrine Society 2024. #ENDO2024 https://lnkd.in/g5pRJcnc https://lnkd.in/g_8mvpe5